The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides
Restricted accessResearch articleFirst published online October, 2017
The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides
Antisense oligonucleotides (ASOs) are widely accepted therapeutic agents that suppress RNA transcription. While the majority of ASOs are well tolerated in vivo, few sequences trigger inflammatory responses in absence of conventional CpG motifs. In this study, we identified non-CpG oligodeoxy-nucleotide (ODN) capable of triggering an inflammatory response resulting in B cell and macrophage activation in a MyD88- and TLR9-dependent manner. In addition, we found the receptor for advance glycation end product (RAGE) receptor to be involved in the initiation of inflammatory response to suboptimal concentrations of both CpG- and non-CpG-containing ODNs. In contrast, dosing RAGE KO mice with high doses of CpG or non-CpG ODNs lead to a stronger inflammatory response than observed in wild-type mice. Together, our data provide a previously uncharacterized in vivo mechanism contingent on ODN-administered dose, where TLR9 governs the primary response and RAGE plays a distinct and cooperative function in providing a pivotal role in balancing the immune response.
MolneL, CollinsLV and TarkowskiA. (2003). Inflammatogenic properties of bacterial DNA following cutaneous exposure. J Invest Dermatol, 121:294–299.
3.
BennettCF. (2007). Pharmacological properties of 2′-O-methoxyethyl-modified oligonucleotides. In: Antisense Drug Technologies, 2nd edn. CrookeST, ed. Taylor & Francis Group, LLC, Boca Raton.
4.
KriegAM. (1996). An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med, 128:128–133.
5.
MonteithDK, HenrySP, HowardRB, FlournoyS, LevinAA, BennettCF and CrookeST. (1997). Immune stimulation—a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des, 12:421–432.
6.
RobertsTL, SweetMJ, HumeDA and StaceyKJ. (2005). Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol, 174:605–608.
7.
BurelSA, MachemerT, RagoneFL, KatoH, CauntayP, GreenleeS, SalimA, GaardeWA, HungG, et al. (2012). Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response. J Pharmacol Exp Ther, 342:150–162.
KawaiT and AkiraS. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 11:373–384.
14.
KawaiT and AkiraS. (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 34:637–650.
15.
KriegAM. (1999). CpG DNA: a novel immunomodulator. Trends Microbiol, 7:64–65.
16.
KriegAM. (2003). CpG motifs: the active ingredient in bacterial extracts?. Nat Med, 9:831–835.
17.
KriegAM, YiAK, MatsonS, WaldschmidtTJ, BishopGA, TeasdaleR, KoretzkyGA and KlinmanDM. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374:546–549.
18.
LandeR, GregorioJ, FacchinettiV, ChatterjeeB, WangYH, HomeyB, CaoW, SuB, NestleFO, et al. (2007). Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 449:564–569.
19.
BartonGM, KaganJC and MedzhitovR. (2006). Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol, 7:49–56.
20.
BauerS, KirschningCJ, HackerH, RedeckeV, HausmannS, AkiraS, WagnerH and LipfordGB. (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A, 98:9237–9242.
21.
TakeuchiO and AkiraS. (2010). Pattern recognition receptors and inflammation. Cell, 140:805–820.
22.
BlasiusAL and BeutlerB. (2010). Intracellular toll-like receptors. Immunity, 32:305–315.
23.
SennJJ, BurelS and HenrySP. (2005). Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther, 314:972–979.
24.
SiroisCM, JinT, MillerAL, BerthelootD, NakamuraH, HorvathGL, MianA, JiangJ, SchrumJ, et al. (2013). RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med, 210:2447–2463.
25.
YamamotoM, SatoS, HemmiH, HoshinoK, KaishoT, SanjoH, TakeuchiO, SugiyamaM, OkabeM, TakedaK and AkiraS. (2003). Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science, 301:640–643.
GlaccumMB, StockingKL, CharrierK, SmithJL, WillisCR, MaliszewskiC, LivingstonDJ, PeschonJJ and MorrisseyPJ. (1997). Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol, 159:3364–3371.
28.
MerazMA, WhiteJM, SheehanKC, BachEA, RodigSJ, DigheAS, KaplanDH, RileyJK, GreenlundAC, et al. (1996). Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell, 84:431–442.
29.
ConstienR, FordeA, LiliensiekB, GroneHJ, NawrothP, HammerlingG and ArnoldB. (2001). Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis, 30:36–44.
30.
WattsLM, ManchemVP, LeedomTA, RivardAL, McKayRA, BaoD, NeroladakisT, MoniaBP, BodenmillerDM, et al. (2005). Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes, 54:1846–1853.
31.
TakadaK and JamesonSC. (2009). Naive T cell homeostasis: from awareness of space to a sense of place. Nat Rev Immunol, 9:823–832.
32.
GeissmannF, AuffrayC, PalframanR, WirrigC, CioccaA, CampisiL, Narni-MancinelliE and LauvauG. (2008). Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol, 86:398–408.
33.
TianJ, AvalosAM, MaoSY, ChenB, SenthilK, WuH, ParrocheP, DrabicS, GolenbockD, et al. (2007). Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol, 8:487–496.
34.
RamasamyR, YanSF and SchmidtAM. (2009). RAGE: therapeutic target and biomarker of the inflammatory response—the evidence mounts. J Leukoc Biol, 86:505–512.
35.
PaludanSR and BowieAG. (2013). Immune sensing of DNA. Immunity, 38:870–880.
36.
IshiiKJ, CobanC, KatoH, TakahashiK, ToriiY, TakeshitaF, LudwigH, SutterG, SuzukiK, et al. (2006). A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol, 7:40–48.
37.
KriegAM. (2006). Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov, 5:471–484.
38.
GalichetA, WeibelM and HeizmannCW. (2008). Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun, 370:1–5.
39.
RaucciA, CugusiS, AntonelliA, BarabinoSM, MontiL, BierhausA, ReissK, SaftigP and BianchiME. (2008). A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J, 22:3716–3727.
40.
ZhangL, BukulinM, KojroE, RothA, MetzVV, FahrenholzF, NawrothPP, BierhausA and PostinaR. (2008). Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem, 283:35507–35516.
41.
KaleaAZ, ReinigerN, YangH, ArrieroM, SchmidtAM and HudsonBI. (2009). Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J, 23:1766–1774.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
